Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | CCR8 | P51685 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642482 | 0.88 | SIGMAR1 (0.72) | SIGMAR1HRH3CCR8 | |
| SCHEMBL4592089 | 0.86 | SIGMAR1 (0.68) | SIGMAR1DRD4KMT2A | |
| SCHEMBL7268908 | 0.86 | SIGMAR1 (0.79) | SIGMAR1CCR8 | |
| Hydrochloric Acid SCHEMBL29640479 | 0.85 | SIGMAR1 (0.77) | SIGMAR1CCR8 | |
| SCHEMBL4591633 | 0.84 | SIGMAR1 (0.65) | SIGMAR1DRD4KMT2A | |
| SCHEMBL4039839 | 0.83 | SIGMAR1 (0.80) | SIGMAR1 | |
| SCHEMBL7487718 | 0.83 | SIGMAR1 (0.74) | SIGMAR1HRH3CCR8KMT2A | |
| SCHEMBL4847113 | 0.79 | SIGMAR1 (0.62) | SIGMAR1DRD4 | |
| SCHEMBL4847104 | 0.79 | SIGMAR1 (0.62) | SIGMAR1DRD4 | |
| SCHEMBL5434322 | 0.78 | SIGMAR1 (0.58) | SIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | SIGMAR1 59/4885HRH3 89/4885DRD4 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.